Gilead seeks FDA approval for remdesivir



Gilead seeks FDA approval for remdesivir

(HealthDay)—Gilead Sciences has utilized to the U.S. Food and Drug Administration for approval for its COVID-19 therapy, remdesivir. The antiviral drug will take the model identify Veklury, the corporate stated.

“Today’s filing is an important milestone as we continue to partner with the U.S. government and health care authorities around the globe to address the treatment needs of patients with COVID-19,” Merdad Parsey, M.D., Ph.D., Gilead’s chief medical officer, stated in a press release.

At the second, remdesivir is accessible on an emergency foundation for hospitalized sufferers with extreme COVID-19. If the FDA approves it, nevertheless, the drug will achieve wider use. Remdesivir is already accredited in Europe and Japan. The request for approval comes after the outcomes of a part three trial. The drug works by blocking the virus from copying itself. Trials of the drug confirmed that it could possibly lower from COVID-19 by almost a 3rd.

“Since the beginning of the pandemic, Gilead has worked with urgency to establish the efficacy and safety profile of Veklury, and we now have a robust data set supporting the evaluation of use of the drug across a range of hospitalized COVID-19 patient populations,” Parsey stated.

Japan approves remdesivir for coronavirus treatment

More info:
More Information

Copyright © 2020 HealthDay. All rights reserved.

Gilead seeks FDA approval for remdesivir (2020, August 12)
retrieved 12 August 2020

This doc is topic to copyright. Apart from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.


Source link

Leave a Reply